Nanomedicines for chronic non-infectious arthritis: The clinicians perspective
Maturitas, 08/21/2012
Rubinstein I et al. – The authors propose that detailed pre–clinical in vivo safety assessment of promising disease–modifying antirheumatic nanomedicines leads for rheumatoid arthritis and osteoarthritis, including risks to the general population, must be conducted before clinical trials begin.



